HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

5-Amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenyl ester (ATB-429), a hydrogen sulfide-releasing derivative of mesalamine, exerts antinociceptive effects in a model of postinflammatory hypersensitivity.

Abstract
H(2)S functions as a neuromodulator and exerts anti-inflammatory activities. Recent data indicate that irritable bowel syndrome (IBS) is linked to inflammation of the gastrointestinal tract. In this study, we have investigated the role of a novel H(2)S-releasing derivative of mesalamine (5-amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenyl ester, ATB-429) in modulating nociception to colorectal distension (CRD), a model that mimics some features of IBS, in healthy and postcolitic rats. Four graded (0.4-1.6 ml of water) CRDs were produced in conscious rats, and colorectal sensitivity and pain were assessed by measuring the abdominal withdrawal response and spinal c-Fos expression. In healthy rats, ATB-429 dose dependently (25, 50, or 100 mg/kg) attenuated CRD-induced hypersensitivity and significantly inhibited CRD-induced overexpression of spinal c-FOS mRNA, whereas mesalamine had no effect. ATB-429-induced antinociception was reversed by glibenclamide, a ATP-sensitive K(+) (K(ATP)) channel inhibitor. The antinociceptive effect of ATB-429 was maintained in a rodent model of postinflammatory hypersensitivity (4 weeks after colitis induction). At a dose of 100 mg/kg, ATB-429 reversed the allodynic response caused by CRD in postcolitic rats. Colonic cyclooxygenase-2 and interkeukin-1beta mRNA and spinal c-FOS mRNA expression were significantly down-regulated by ATB-429, but not by mesalamine. ATB-429, but not mesalamine, increased blood concentrations of H(2)S in both healthy and postcolitic rats. Taken together, these data suggest that ATB-429 inhibits hypersensitivity induced by CRD in both healthy and postcolitic, allodynic rats by a K(ATP) channel-mediated mechanism. This study provides evidence that H(2)S-releasing drugs might have beneficial effects in the treatment of painful intestinal disorders.
AuthorsEleonora Distrutti, Luca Sediari, Andrea Mencarelli, Barbara Renga, Stefano Orlandi, Giuseppe Russo, Giuseppe Caliendo, Vincenzo Santagada, Giuseppe Cirino, John L Wallace, Stefano Fiorucci
JournalThe Journal of pharmacology and experimental therapeutics (J Pharmacol Exp Ther) Vol. 319 Issue 1 Pg. 447-58 (Oct 2006) ISSN: 0022-3565 [Print] United States
PMID16855178 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • 5-amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-(1,2)dithiol-3yl)phenyl ester
  • Analgesics
  • Disulfides
  • Potassium Channel Blockers
  • Mesalamine
  • Hydrogen Sulfide
Topics
  • Analgesics (pharmacology)
  • Animals
  • Colon (drug effects, metabolism)
  • Disulfides (pharmacokinetics, pharmacology)
  • Hydrogen Sulfide (metabolism)
  • Irritable Bowel Syndrome (drug therapy)
  • Male
  • Mesalamine (pharmacokinetics, pharmacology)
  • Potassium Channel Blockers (pharmacology)
  • Rats
  • Rats, Wistar
  • Spinal Cord (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: